Mexico rejects Nestle's buyout of Pfizer nutrition unit; Apotex sues Daiichi over Benicar patent;

@FiercePharma: Novartis nabs FDA approval for 1st flu vaccine made without eggs. Produced at plant that got $500M in gov't aid. More (sub. req.) | Follow @FiercePharma

> Mexican regulators blocked Nestle's acquisition of Pfizer's ($PFE) nutrition unit in that country, saying the deal would give Swiss-based Nestle up to 88% of the baby formula market, clearing the way for price increases. Report

> Apotex petitioned a U.S. court to rule that its plan to sell a generic version of Daiichi Sankyo's Benicar blood pressure drug wouldn't step on the Japanese company's patents. Report

> The American College of Obstetricians and Gynecologists recommended that birth control pills be made available over the counter. Report

> Administering the sleep drug Ambien or its combination-pill sister Intermezzo to hospital patients may help them rest but may also substantially increase their risk of a fall, a study found. Report

> The WHO said that drug marketing practices may amp up antibiotic use in a way that facilitates the spread of superbugs. Report

> Xoma's ($XOMA) combination of two generic hypertension drugs lowered blood pressure than either of the drugs alone, a study found. Report

Medical Device News

 @FierceMedDev: FDA faults St. Jude's manufacturing for Durata ICD leads. St. Jude disclosed the report but kept "Durata" out. More | Follow @FierceMedDev

 @MarkHFierce: Zimmer will train regulators in China in an unusual deal. Release | Follow @MarkHFierce

 @DamianFierce: Novartis' Alcon is buying the ophthalmic surgery unit of German company SensoMotoric. Story | Follow @DamianFierce

> Boston Scientific gets CE mark for expanded CRM longevity. Article

> HeartWare snags FDA approval for novel heart pump. News

Biotech News

 @FierceBiotech: Predicting your end: Biomarkers for mortality. News | Follow @FierceBiotech

 @JohnCFierce: Feds zero in on drug experts as insider case exposes investigator's role (more to come, I suspect). Story | Follow @JohnCFierce

 @RyanMFierce: With ex-BMSer Jeremy Levin at the helm, Teva wants to do buyouts that are smaller than the deals that made Teva big. More | Follow @RyanMFierce

> Xoma hunts for marketing partner as blood pressure med clears PhIII. Article

> Pfizer, Bristol-Myers win landmark European approval for Eliquis. Story

Drug Delivery News

> Fujifilm joins microneedle R&D boom. Report

> Reinforced gels deliver drugs and cells. Article

> Pfizer hits ups, downs with controlled-release Lyrica. News

> Nanoparticles deliver antigen to trick the immune system in MS. Story

Biomarkers News

> Predicting your end: Biomarkers for mortality. Article

> Kidney problems tag development delays? Story

> Saliva markers diagnose gum disease. News

> DoD's $1.15M grant may lead to blood test to catch heavy drinkers. Item

Vaccine News

> J&J hits development roadblock with Crucell candidates. Article

> FDA panel concerned about safety of Dynavax's hep B vaccine. News

> Novartis nabs EU committee backing for meningitis B vaccine. Story

> GSK's Synflorix gleans positive results in infants. Report

> FDA approves Novartis flu vaccine. Item

And Finally... U.S. officials tracking down the purveyors of fake Avastin may find common cause with Mark Twain, who lambasted a bogus medicine salesman in a scathing 1905 letter. Report | Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.